Zirconium Zr 89 Crefmirlimab Berdoxam
Urinary Bladder Neoplasm
Explore 24 assets in Urinary Bladder Neoplasm →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
antibody_drug_conjugate
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05397171CT.gov A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urinary Bladder Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Zirconium Zr 89 Crefmirlimab Berdoxam (this asset) | AstraZeneca | P1/2 | CCC · 48 |
| Carboplatin | Merck Sharp & Dohme LLC | P2 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Eli Lilly and Company | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Merck Sharp & Dohme LLC | P2 | BB |
| Pembrolizumab | Eli Lilly and Company | P2 | BB |
| Nivolumab | Ikena Oncology | P2 | B |
| 5-fluoro-2-deoxycytidine | National Cancer Institute (NCI) | P2 | B |
| Tetrahydrouridine | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab/Vibostolimab Coformulation | Merck Sharp & Dohme LLC | P2 | B |
+28 more in the Urinary Bladder Neoplasm cohort
Other indications for Zirconium Zr 89 Crefmirlimab Berdoxam
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2/3 | B · 58 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P2 | CCC · 53 |
| Melanoma | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CarboplatinMerck Sharp & Dohme LLCBB
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Eli Lilly and CompanyBB
- Cis-Diamminedichloroplatinum IiMerck Sharp & Dohme LLCBB
- PembrolizumabEli Lilly and CompanyBB
- NivolumabIkena OncologyB
Citation
Floatz Terminal. Zirconium Zr 89 Crefmirlimab Berdoxam in Urinary Bladder Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/zirconium-zr-89-crefmirlimab-berdoxam-urinary-bladder-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →